Investigational Cream Promising for Epidermolysis Bullosa
-
An investigational cream containing a concentrated form of an old active ingredient might offer new hope for patients with all three major types of epidermolysis bullosa, results from a phase 2b trial suggest. At 2 months, wound healing was significantly better with a 6% concentration of SD-101 (Zorblisa, Scioderm) than with vehicle placebo in patients with epidermolysis bullosa.
-
@mohitpriya In 2013, SD-101 was granted breakthrough therapy designation by the US Food and Drug Administration for the treatment of patients with inherited epidermolysis bullosa. Such designation "is very unusual, but of course reflects the terrible issues we've had with this disorder," said Amy Paller, MD, from the Feinberg School of Medicine at Northwestern University in Chicago. The SD-101 6% concentration is now being tested in a larger phase 3 study, Dr Paller reported here at the American Academy of Dermatology 74th Annual Meeting.